US Patent Issued to Alnylam Pharmaceuticals on March 24 for "Angiotensinogen (AGT) iRNA compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,584,130, issued on March 24, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Angiotensinogen (AGT) iRNA compositions and methods of use thereof" was invented by Donald Foster (Attleboro, Mass.), Gregory Hinkle (Plymouth, Mass.) and Mark K. Schlegel (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure."

The patent was filed on Oc...